MOSCOW and PORTLAND, Ore., April 28, 2020 (GLOBE NEWSWIRE) -- R-Pharm JSC and Cromos Pharma today announced that it has randomized the first patients into a clinical trial evaluating Olokizumab and RPH-104 in patients with severe COVID-19 infection. Olokizumab (OKZ) is a humanized monoclonal antibody with high affinity for interleukin-6 (IL-6), and RPH-104 is a fusion protein that selectively binds and inactivates interleukin-1ß (IL-1ß). The overactive inflammatory response also called the “cytokine storm” has been implied to play a major role in progression of COVID-19 infection. By blocking the two most critical proinflammatory cytokines and thus inhibiting the inflammation cascade, OKZ and RPH-104 may suppress the development of Acute Respiratory Distress Syndrome (ARDS), the leading cause of death in patients with COVID-19.
Contract manufacturing and packaging organisations that have joined the Life Sciences Cloud to leverage TraceLink’s network-tenant platform and rapidly connect with their brand-owners include: Allpack, Alpex, Central Pharma, Fareva SA, Groupe SYNERLAB, Inforlife, Laboratoires Famar FFH, Laboratorios Liconsa, Patheon, Pharmidea R-Pharm, Recipharm, Ropack, Sharp, S.M.B. Technology, Tesa, Tjoapack, Tubilux, Unitax and WDsrX.